Motif Bio PLC (MTFB) Stock Rating Reaffirmed by Beaufort Securities
Beaufort Securities reissued their speculative buy rating on shares of Motif Bio PLC (LON:MTFB) in a research note released on Monday morning. The firm currently has a GBX 110 ($1.46) target price on the stock.
MTFB has been the topic of several other reports. FinnCap reissued a buy rating and issued a GBX 100 ($1.33) target price on shares of Motif Bio PLC in a research report on Thursday, August 24th. Northland Securities reissued a buy rating on shares of Motif Bio PLC in a research report on Friday, September 29th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of GBX 101.50 ($1.35).
Shares of Motif Bio PLC (MTFB) opened at 43.25 on Monday. The company’s market capitalization is GBX 113.69 million. Motif Bio PLC has a 12 month low of GBX 21.44 and a 12 month high of GBX 53.50. The stock’s 50 day moving average price is GBX 30.36 and its 200 day moving average price is GBX 30.54.
COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/10/06/motif-bio-plc-mtfb-stock-rating-reaffirmed-by-beaufort-securities.html.
Motif Bio PLC Company Profile
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Stock Ratings for Motif Bio PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio PLC and related stocks with our FREE daily email newsletter.